Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
Retroviruses associated with leukemia and ablative syndromes in animals and in human beings.
Cancer Res. 1985 Sep;45(9 Suppl):4534s-4538s. Unique Identifier : AIDSLINE MED/85254465 Essex M; McLane MF; Kanki P; Allan J; Kitchen L; Lee TH
Abstract:
T-lymphotropic retroviruses of cats cause lymphopenia and immunosuppression and represent the major cause of death in that species. Similarly HTLV-I which is T4 tropic is associated with an increased risk for development of infectious disease in regions where the virus is endemic. Since HTLV-I is also believed to be transmitted by blood and by sexual intercourse we considered the possibility that a variant form of HTLV might cause AIDS. The identification of cross-reactive antibodies to HTLV-I-MA in a third or more of the AIDS patients and in suspicious blood donors that donated to transfusion-associated cases of AIDS eventually led to the recognition of HTLV-III, the causative agent of AIDS. The protein most associated with lymphocyte immortalization or transformation in the case of HTLV-I is p42. The proteins of HTLV-I encoded by the amino terminus of the env gene designated gp61 and gp45 are the most immunogenic antigens of this virus. Similarly those encoded by the amino terminus of the env gene HTLV-III designated gp160 and gp120 appear to be the most immunogenic markers for this agent. Almost all AIDS patients, ARC patients, and asymptomatic hemophiliacs have detectable antibodies to gp120 and gp160. HTLV-III related agents designated STLV-III have been found in macaque monkeys that develop simian AIDS and high prevalence rates of antibodies to STLV-III can be found in healthy African green monkeys. We hypothesize that the STLV-III of African green monkeys could represent a recent source of the virus to have infected humans in central Africa where the human epidemic probably began. The recognition that up to one million people may already be infected with HTLV-III in the United States alone indicates the need for development of a vaccine. The availability of primate species infected with the serologically related STLV-III agents that either resist disease development (African green monkeys) or succumb to an AIDS-type syndrome (rhesus) provide models that should aid in our attempts to develop such vaccines.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*MICROBIOLOGY/ TRANSMISSION Animal Antibodies, Viral/ANALYSIS Antigens, Viral/IMMUNOLOGY Blood Transfusion Cat Diseases/MICROBIOLOGY Cats Cell Transformation, Viral Cercopithecus aethiops Genes, Viral Hemophilia/IMMUNOLOGY Human *HTLV-BLV Viruses/ANALYSIS/GENETICS/IMMUNOLOGY Leukemia/MICROBIOLOGY/VETERINARY Leukemia Virus, Feline Macaca mulatta Male Monkey Diseases/IMMUNOLOGY/MICROBIOLOGY Oncogenes Retroviridae/IMMUNOLOGY/ISOLATION & PURIF Retroviridae Infections/IMMUNOLOGY/MICROBIOLOGY/VETERINARY Support, U.S. Gov't, P.H.S. Viral Envelope Proteins/ANALYSIS/IMMUNOLOGY Viral Proteins/GENETICS/PHYSIOLOGY JOURNAL ARTICLE REVIEW
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
